Showing results (341-350 of 357) with videos related to

Sort By:
Pageof 36
JAMA|June 8, 2006
Sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialBernard Escudier, Tim Eisen, Walter M Stadler, et al.
The New England Journal of Medicine|January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinomaBernard Escudier, Tim Eisen, Walter M Stadler, et al.
The Journal of Urology|July 19, 2008
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinomaToni K Choueiri, Susan A J Vaziri, Erich Jaeger, et al.
International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyKenneth A Foon, Xiao-Dong Yang, Louis M Weiner, et al.
Clinical Genitourinary Cancer|December 28, 2020
Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a CureBrian Rini, E Jason Abel, Laurence Albiges, et al.
British Journal of Cancer|March 18, 2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsE Van Cutsem, P M Hoff, P Harper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaRobert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.
Cancer|April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge ConferenceMichael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
Pageof 36